A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Clinical trial NCT06907043 · RECRUITING

Trial details

NCT number: NCT06907043
Sponsor: Eikon Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2025-04-30
Primary completion: 2028-12-01
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.